Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells

Exploring and comparing adverse events between PARP inhibitors

(2019) Christopher J LaFargue et al.   LANCET ONCOLOGY

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

(2019) Kalindi Parmar et al.   CLINICAL CANCER RESEARCH

Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition

(2018) Brittany Haynes et al.   CANCER TREATMENT REVIEWS

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer

(2017) Ethan Brill et al.   Oncotarget

Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy

(2016) Andrew J. Massey   CANCER LETTERS

Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer Models

(2016) Hyoung Kim et al.   CLINICAL CANCER RESEARCH

Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword

(2016) Roberta Visconti et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

(2016) Mansoor R. Mirza et al.   NEW ENGLAND JOURNAL OF MEDICINE

CHK1 and RAD51 activation after DNA damage is regulated via urokinase receptor/TLR4 signaling

(2016) Pavan B Narayanaswamy et al.   Cell Death & Disease

Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance

(2015) Peter Bai   MOLECULAR CELL

Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition

(2015) Fiona K. Middleton et al.   Oncotarget

Ovarian cancer standard of care: are there real alternatives?

(2015) Chiara Della Pepa et al.   Chinese Journal of Cancer

PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells

(2013) Laurence Booth et al.   CANCER BIOLOGY & THERAPY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells

(2010) P. Gottipati et al.   CANCER RESEARCH

Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors

(2010) A. Mukhopadhyay et al.   CLINICAL CANCER RESEARCH

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

(2008) R. Plummer et al.   CLINICAL CANCER RESEARCH